Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azelastine hydrochloride + diquafosol
- Development stage
- Preclinical
- Lead developer
- Santen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Azelastine hydrochloride + diquafosol is a fixed-dose combination of two ophthalmic agents used primarily for the treatment of allergic conjunctivitis in patients who also have dry eye disease. Azelastine hydrochloride is a second-generation antihistamine that acts as a selective histamine H1 receptor antagonist and mast cell stabilizer, reducing allergic symptoms such as itching and inflammation by blocking histamine release and other inflammatory mediators. Diquafosol is a P2Y2 purinergic receptor agonist that stimulates tear fluid and mucin secretion on the ocular surface, improving tear film stability and alleviating dry eye symptoms. The combination targets both the allergic (itching/inflammation) and dry eye components of ocular surface disease, providing synergistic relief for patients with overlapping conditions[1][2][5].
- Other names
- azelastine + diquafosolazelastine hydrochloride and diquafosol3% diquafosol combined with azelastine hydrochloride
02
Targets
P2RY2 (P2Y Purinoceptor 2)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on azelastine hydrochloride + diquafosol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azelastine hydrochloride + diquafosol.